Czechia· CZ-0253027
ESLIKARBAZEPIN NEURAXPHARM
A eslicarbazepine product containing eslicarbazepine acetate, registered in Czechia by Neuraxpharm Bohemia s.r.o., Praha. The same ATC class is registered in 16 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Eslicarbazepine is registered in 16 of 19 countries.
Countries holding a registration under ATC N03AF04 (eslicarbazepine), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 10 of them publish a price we can compare per daily dose
Eslicarbazepine · ATC N03AF04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of eslicarbazepine costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), the median price runs from $2.32 in Italy to $4.08 in Switzerland — a ×1.8 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Eslicarbazepine · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$4.08
- ES Spain$3.49
- IT Italy$2.32
The record
At a glance
SÚKL (Czech Republic)- Active substance
- ESLICARBAZEPINE ACETATE
- Manufacturer
- Neuraxpharm Bohemia s.r.o., Praha
- Country
- Czechia (CZ)
- ATC code
- N03AF04
- ATC class
- Eslicarbazepine
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
188 interactions on record for eslicarbazepine.
Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eslicarbazepine · interactions on record
188 records
- 17 severe
- 166 moderate
- 5 minor
Most severe, free to view
- Levonorgestrel and ethinylestradiolG03AA07severe
- Desogestrel and ethinylestradiolG03AA09severe
- Drospirenone and ethinylestradiolG03AA12severe
- EthinylestradiolG03CA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Eslicarbazepine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAptiomSumitomo Pharma America, Inc.
- SpainESCARPILO 400 MG COMPRIMIDOS EFGNeuraxpharm Spain S.L.
- NetherlandsEslibon 400 mg tablettenG.L. Pharma GmbH
- PolandEslibonG.L. Pharma GmbH
- IcelandZebinixBial - Portela & C. S.A.
- FinlandZebinixBial Portela & C, S.A.
- IrelandZebinix 400 mg TabletBIAL-Portela & Ca, S.A.
- CanadaAPTIOMSUMITOMO PHARMA CANADA, INC.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Eslibon
- Bulgaria · Еслибон
- Cyprus · Esran
- Germany · Eslibon, Eslicarbazepin Al
- Denmark · Arupsan, Eslicarbazepinacetat "stada"
- Spain · Arupsan, Bixcar
- France · Eslicarbazepine 800, Eslicarbazepine Arrow
- United Kingdom (Northern Ireland) · Arupsan, Eslicarbazepine Amarox
- Greece · Esran
- Hungary · Eslicarbazepine 800
- Iceland · Eslicarbazepin, Eslicarbazepine Acetate Stada
- Italy · Arupsan, Eslicarbazepina Acetato Aurobindo
- Liechtenstein · Zebinix
- Malta · Esran
- Netherlands · Eslibon
- Norway · Zebinix
- Poland · Eslibon
- Portugal · Acetato De Eslicarbazepina Alter, Acetato De Eslicarbazepina Aristo
- Sweden · Arupsan
- Slovakia · Eslibon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/62f690be-112e-4a10-b266-693741e66db9 GET /v1/drugs/62f690be-112e-4a10-b266-693741e66db9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL NOB",
"source": "sukl",
"strength": "400MG",
"pack_size": "15",
"substance": "ESLICARBAZEPINE ACETATE",
"cz_kod_sukl": "0253027",
"product_type": "CH",
"substance_codes": "18496",
"registration_state": "R",
"registration_number": "21/122/21-C"
}See everything about eslicarbazepine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.